Analysts Offer Insights on Healthcare Companies: Teva Pharma (NYSE: TEVA) and Valeant Pharma (NYSE: VRX)

By Ryan Adsit

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Teva Pharma (NYSE: TEVA) and Valeant Pharma (NYSE: VRX).

Teva Pharma (NYSE: TEVA)

In a report released yesterday, Randall Stanicky from RBC Capital reiterated a Buy rating on Teva Pharma (NYSE: TEVA), with a price target of $38. The company’s shares closed yesterday at $30.92, close to its 52-week low of $27.60.

According to TipRanks.com, Stanicky is ranked 0 out of 5 stars with an average return of -9.9% and a 31.4% success rate. Stanicky covers the Healthcare sector, focusing on stocks such as Pacira Pharmaceuticals, Eagle Pharmaceuticals, and Jazz Pharmaceuticals.

Teva Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $37.40.

Valeant Pharma (NYSE: VRX)

RBC Capital analyst Douglas Miehm reiterated a Hold rating on Valeant Pharma (NYSE: VRX) yesterday and set a price target of $19. The company’s shares closed yesterday at $12.66.

According to TipRanks.com, Miehm is ranked 0 out of 5 stars with an average return of -14.7% and a 23.3% success rate. Miehm covers the Healthcare sector, focusing on stocks such as Novelion Therapeutics Inc, Cardiome Pharma Corp, and Concordia Healthcare.

Currently, the analyst consensus on Valeant Pharma is Hold and the average price target is $15.09, representing a 19.2% upside.

In a report issued on June 8, BMO Capital also maintained a Hold rating on the stock with a $15 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.